Jasper Therapeutics Q3 net loss widens to $144.46 million
JSPR•Jasper Therapeutics reported a third-quarter FY26 net loss of $144.46 million and revenue of $8 million; cash and cash equivalents totaled $135.35 million on September 30, 2026.
JSPR•Jasper Therapeutics reported a third-quarter FY26 net loss of $144.46 million and revenue of $8 million; cash and cash equivalents totaled $135.35 million on September 30, 2026.
Jasper Therapeutics' third-quarter FY26 net loss widened to $144.46 million, while revenue reached $8 million. Research and development expense fell 42% year over year to $8.33 million, and general and administrative expense rose 33% to $6.36 million. Acquired in-process research and development expense totaled $129.49 million.
Enrollment in the first Phase 2 vensobafusp alfa IgA nephropathy cohort finished, with interim data expected in the fourth quarter of 2026.